Latest / International Business with Fexingo: Global Trade, Cross-Border Deals, and Multinational Operations / How India Is Becoming the Worlds Factory for Generic Drugs
Transcript
- Lucas: So this week, India's pharmaceutical export council released its numbers for the first quarter of the fiscal year, and they show that generic drug exports hit a record $7.2 billion in April and May alone. Luna: That's a big leap. What's driving it? Low cost or something else? Lucas: It's a combination, but the core is that India now supplies over 20 percent of the world's generic drugs by volume. And it's not just the cheap stuff — think complex generics like injectables and inhalers. The industry has been investing heavily in vertical integration, especially in active pharmaceutical ingredients, or APIs. Luna: Right, because for years they relied on China for those raw materials. So now they're building their own API capacity? Lucas: Exactly. And it's paying off. Take a company like Sun Pharma or Dr. Reddy's — they've both expanded their own API manufacturing, which insulates them from supply shocks and improves margins. The US FDA approved 77 abbreviated new drug applications from Indian firms just last year, which is the highest ever. Luna: So the US is still the biggest market for them? Even with all the talk about reshoring? Lucas: Yes, the US remains the largest destination, about 30 percent of India's pharma exports. But what's interesting is that Africa and Southeast Asia are growing faster. India now supplies over 60 percent of Africa's generic medicines. That's a huge strategic foothold. Luna: And the weaker dollar helps. We saw the trade-weighted dollar index dip to 119.5 last week. Indian pharma companies earn mostly in dollars but pay costs in rupees, so that's a direct tailwind. Lucas: That's a great point. Every one percent depreciation in the rupee against the dollar adds roughly 30 to 40 basis points to operating margins for these companies. And the rupee has weakened slightly over the past month. The iShares MSCI India ETF, ticker i n d a, was up 2.6 percent just this week, partly on pharma strength. Luna: But there's a risk here. The US is pushing for more drug manufacturing onshore. The BIOSECURE Act, for example, targets Chinese biotech, but could it also impact Indian firms? Lucas: It could, but the reality is that Indian companies have built deep relationships with US hospitals and pharmacy chains. They're not just suppliers — they're partners in drug development. And the cost advantage is still massive. A course of a generic drug from India can be 80 percent cheaper than the us branded version. Luna: So the moat is real. But are there any cracks? I've read about quality control issues at some plants. Lucas: There have been, yes. The FDA has issued warning letters to a few facilities. But the industry has responded. The larger players have invested in compliance and automation. And honestly, the global demand for affordable medicines is so high that even with occasional hiccups, buyers stick with Indian suppliers because the alternatives are much more expensive. Luna: Let's zoom out. How does this fit into India's broader trade story? We've talked about IT services and R&D. Is pharma the next pillar? Lucas: Absolutely. India's pharma exports are now over $25 billion annually, and growing at 8 to 10 percent year-over-year. That's comparable to the IT services export numbers. And unlike IT, which faces visa restrictions and automation threats, drug manufacturing has a physical product that can't be replaced by AI. Luna: So if these conversations have moved your work forward in some small way, you can support the show at buy me a coffee dot com slash fexingo. That's buy me a coffee dot com slash fexingo. Helps us keep things ad-free and focused on the data. Lucas: Yeah, really appreciate that. So back to the story — one more data point I think is telling. The Indian government just launched a $2 billion production-linked incentive specifically for complex generics and biosimilars. Luna: That's a direct bet on moving up the value chain. Biosimilars are harder to make, higher margin, and patents are expiring on some big biologics. Lucas: Right. And Indian companies like Biocon and Intas already have approved biosimilars in the US and Europe. The next five years could see India capture a significant share of the global biosimilar market, which is expected to reach $100 billion by 2030. Luna: So the trajectory is clear. India is becoming the world's pharmacy, not just for cheap pills but for complex, high-tech drugs. Lucas: And that has implications for global trade flows, drug pricing, and public health. It's a shift that rivals what we saw with electronics in East Asia. Definitely one to watch.